BAM
STRO icon

Blueshift Asset Management’s Sutro Biopharma STRO Stock Holding History

Blueshift Asset Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,319
Closed -$245K – 1288
2021
Q2 		$245K Buy
+1,319
New +$258K 0.01% 784

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Blueshift Asset Management's STRO Position: Q3 2021 in Review

Blueshift Asset Management sold out of Sutro Biopharma (STRO) in Q3 2021, closing a stake of 1,319 shares — an estimated $245K sold.

Blueshift Asset Management first reported a position in STRO in Q2 2021 and held it in 1 quarter. The position peaked at $245K in Q2 2021. 120 funds tracked by Wall St. Rank hold STRO as of Q3 2021.

  • Blueshift Asset Management reported no remaining Sutro Biopharma position as of Q3 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 1,319 Sutro Biopharma shares in Q3 2021, an estimated $245K.
  • Blueshift Asset Management first reported a position in Sutro Biopharma in Q2 2021 and held it in 1 quarter.
  • Blueshift Asset Management's Sutro Biopharma position peaked at $245K in Q2 2021.
  • 120 funds tracked by Wall St. Rank held Sutro Biopharma as of Q3 2021.

Based on Blueshift Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.